BBLG (BBLG)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-01-21

Key Insights

Insider Jeff Frelick, the CEO, has disposed of 360 shares of Bone Biologics Corp (BBLG) on January 8, 2026.
Frelick has been granted additional employee stock options, including 16,668 options at $1.55 exercise price and 9,019 options at $5.82 exercise price.
The reported stock option grants and disposal of shares suggest some changes in Frelick's equity position in the company, which investors should monitor for potential implications.

Insider Trading Filed: 2026-01-21

Key Insights

Deina H. Walsh, the Chief Financial Officer of Bone Biologics Corp, made a small sale of 313 shares on January 8, 2026, reducing her direct holdings in the company.
The filing also shows that Walsh was granted two stock options under the company's equity incentive plan - one for 8,335 shares at an exercise price of $1.55, and another for 4,510 shares at an exercise price of $5.82.
The options are intended to align the interests of the executive with the company's long-term performance, as the $1.55 option vests immediately and the $5.82 option is fully vested.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.